Expert Profile
Jan D. Hirsch
Founding Dean, School of Pharmacy and Pharmaceutical Sciences
Jan Hirsch's research interests are focused in the areas of pharmacoeconomics and outcomes research.
Areas of Expertise
- Comprehensive Medication Management (CMM)
- Medication Therapy Management
- Clinical Pharmacy
- Pharmacoeconomics
- Drug Development
- Gout Impact Scale
- Pharmaeutical Services
- Disease-specific Instruments
- Health Related Quality of Life
Biography
Dr. Jan D. Hirsch is Founding Dean of the University of California Irvine School of Pharmacy and Pharmaceutical Sciences and also Professor of Clinical Pharmacy. She is a Distinguished Scholar and Fellow of the National Academies of Practice (NAP) in Pharmacy, and Distinguished Fellow of the Get the Medications Right (GTMRx) Institute, and joined UC Irvine in January of 2019.
Previously she was Professor of Clinical Pharmacy and Chair of the Division of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences, at the University of California, San Diego. She was also Executive Director of an outreach program of the school providing medication therapy management services in the community. She received her B.S. in Pharmacy and M.S. and Ph.D. degrees in Pharmacy Administration from the University of South Carolina, College of Pharmacy. Prior to returning to academia, she spent 14 years in the pharmaceutical and managed care industries where she was responsible for establishing and managing outcomes research departments for two pharmaceutical companies (Glaxo Group Research in Greenford (UK) and Allergan (US)) and a pharmacy benefit management company (Prescription Solutions (US)).
Dr. Hirsch's research interests are focused in the areas of pharmacoeconomics and outcomes research. Specifically, i) assessing the full value (economic, clinical and humanistic) of pharmacy services and pharmaceuticals and ii) integrating patient reported outcomes (PRO's) [e.g. Health Related Quality of Life (HRQOL)] into pharmaceutical and medical practice to improve patient management.
She has served as PI or Co-PI for many studies evaluating the clinical, economic and humanistic outcomes for patients receiving novel pharmacy services for diabetes, hypertension, mental health, and HIV/AIDS. This research has been recognized by state and federal agencies, professional pharmacy organizations and the interdisciplinary National Academies of Practice. Dr. Hirsch has also been the PI for studies creating and/or validating four HRQOL instruments [Functional Living Index Emesis (FLIE), Ocular Surface Disease Index (OSDI), Gout Impact Scale (GIS), Heart Transplant Treatment Burden Questionnaire (HTBQ)] and a method for measuring medication regimen complexity (MRCI). Each of these has been an important contribution to clinical practice and research as evidenced by their uptake by other researchers and inclusion in more than 100 clinical trials.
Media
Media Appearances
Should Kids Take Ozempic, Wegovy? The Idea Has Some Experts Worried
HealthDay, 8/30/2023
Pharmacists in Nontraditional Roles Are Not Included in Bureau of Labor Statistics Count of Working Pharmacists
Pharmacy Times, 2/14/2023
UC Irvine welcomes inaugural class of pharmacy school with white coat ceremony
Daily Pilot, 9/24/2021
UCI to welcome inaugural Pharm.D. class with white coat ceremony
Drug Store News, 9/14/2021
Gaps Feared if Hospitals, Pharmacies Sole Covid Vaccine Source
Bloomberg, 1/8/2021
New faculty faces
UCI News, 10/14/2019
Articles
National survey of physicians’ perspectives on pharmacogenetic testing in solid organ transplantation. Clinical Transplantation.
PubMed, 1/1/1970
Local pharmacies can reduce the dual risks of COVID19 and influenza this fall. Now is the time to prepare.
The Hill, 1/1/1970
PaCIR: A Tool to Enhance Pharmacist Patient Care Intervention Reporting
Journal of the American Pharmacists Association, 1/1/1970
Patterns of Stress, Coping and Health-Related Quality of Life in Doctor of Pharmacy Students
American Journal of Pharmaceutical Education, 5/20/2024
Improved glycemic control outcomes regardless of mental health disorders in a pharmacist-endocrinologist diabetes intense medical management (DIMM) “tune up” clinic.
Annals of Pharmacotherapy, 1/1/1970
Advancing Pharmacist Collaborative Care within Academic Health Systems
Pharmacy, 1/1/1970
Evaluation of a Short, Interactive Diabetes Self-Management Program by Pharmacists for Type 2 Diabetes
BMC Research Notes, 1/1/1970
Federal and Patient Spending on Ten Most Expensive Medications in Medicare Part D from 2011 to 2015
Journal of the American Geriatrics Society, 1/1/1970
Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management “Tune-Up” Clinic
Journal of Managed Care & Specialty Pharmacy, 1/1/1970
Cost of Prescription Drug-Related Morbidity and Mortality
Annals of Pharmacotherapy, 1/1/1970
Economic Impact of and Treatment Options for Type 2 Diabetes
American Journal of Managed Care, 1/1/1970
Estimated Cost-Effectiveness, Cost-Benefit, and Risk Reduction Associated with a Pharmacist-Endocrinologist Diabetes Intense Medical Management “Tune Up” Clinic.
Journal of Managed Care and Specialty Pharmacy, 1/1/1970
Strategies for Addressing the Cost of Nonadherence in Diabetes
American Journal of Managed Care, 1/1/1970
Student Pharmacists' Perceptions of Immunizations
Currents in Pharmacy Teaching and Learning, 1/1/1970
Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management “Tune Up” Clinic in Complex Patients
Annals of Pharmacotherapy, 1/1/1970
Primary Care–based, Pharmacist–physician Collaborative Medication-therapy Management of Hypertension: A Randomized, Pragmatic Trial
Clinical Therapeutics, 1/1/1970
Changes in medication regimen complexity and the risk for 90-day hospital readmission and/or emergency department visits in U.S. Veterans with heart failure
Res Social Adm Pharm, 1/1/1970
Validation of a Patient‐Level Medication Regimen Complexity Index as a Possible Tool to Identify Patients for Medication Therapy Management Intervention
Pharmacotherapy, 1/1/1970
A Composite Endpoint Measure to Consolidate Multidimensional Impact of Treatment on Gouty Arthritis
Open Journal of Rheumatology and Autoimmune Diseases, 1/1/1970
Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis‐related health outcomes measures
International Journal of Clinical Practice, 1/1/1970
Navigating complex patients using an innovative tool: The MTM Spider Web
Journal of American Pharmacists Association, 1/1/1970
Patient-level medication regimen complexity in older adults with depression
Clinical Therapeutics, 1/1/1970
Development of a Pharmacist-Psychiatrist Collaborative Medication Therapy Management (MTM) Clinic
Journal of the American Pharmacists Association, 1/1/1970
Documenting and Describing the Value of Medication Therapy Management Services (MTMS) and Outcomes in Community Pharmacy: Methods and Case Study
California Pharmacist, 1/1/1970
Patient-Level Medication Regimen Complexity Across Populations with Chronic Disease
Clinical Therapeutics, 1/1/1970
Antiretroviral Therapy Adherence, Medication Use, and Health Care Costs During 3 Years of a Community Pharmacy Medication Therapy Management Program for Medi-Cal Beneficiaries with HIV/AIDS
Journal of Managed Care Pharmacy, 1/1/1970
Minimally Important Differences of the Gout Impact Scale in a Randomized Controlled Trial
Rheumatology (Oxford), 1/1/1970
Health Care Utilization in Patients with Gout.
Seminars in Arthritis and Rheumatism, 1/1/1970
Impact of Gout on Health Related Quality of Life and the Relationship to Gout Characteristics
Patient Related Outcome Measures, 1/1/1970
Medication Therapy Management Services in Community Pharmacy: A Pilot Program in HIV Specialty Pharmacies
Journal of Evaluation in Clinical Practice, 5/20/2024
Pharmacists as Immunizers: A California Survey
California Pharmacist, 1/1/1970
Predictors of Doctor-Rated and Patient-Rated Gout Severity: Gout Impact Scales Improve Assessment
Journal of Evaluation in Clinical Practice, 1/1/1970
Comparison of Pharmacists and Primary Care Providers as Immunizers
The American Journal of Pharmacy Benefits, 1/1/1970
Students’ Health-Related Quality of Life Across the Preclinical Pharmacy Curriculum
American Journal of Pharmaceutical Education, 1/1/1970
Evaluation of an Instrument Assessing Gout Impact on Health-Related Quality of Life
Journal of Rheumatology, 1/1/1970
Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries
Journal of Managed Care Pharmacy, 1/1/1970
Patient request for pharmacist counseling and satisfaction: Automated prescription delivery system vs. regular pick-up counter
Journal of the American Pharmacists Association, 1/1/1970
Education
University of South Carolina
MS, Pharmacy Administration, 1982
University of South Carolina
Ph.D., Pharmacy Administration, 1986
University of South Carolina
BS, Pharmacy, 1980
Accomplishments
- Distinguished Scholar and Fellow National Academies of Practice in Pharmacy (NAP)
- Distinguished Fellow of Get the Medications Right Institute (GTMRx)
- Excellence in Teaching Award
- Distinguished Alumni Award
Affiliations
- American Pharmaceutical Association (APhA)
- Academy of Managed Care Pharmacy (AMCP)
- American Association of Colleges of Pharmacy (AACP)
- California Pharmacists Association (CPhA)
- National Academies of Practice (NAP)
- Applied Pharmacoeconomics and Outcomes Research Forum
- Get the Medications Right (GTMRx) Institute
Research Focus
Gout disease-specific quality of life and the association with gout characteristics
7/1/2010
Evaluation of an Instrument Assessing Influence of Gout on Health-Related Quality of Life
12/1/2008
Research Grants
Assessment of Stakeholder Perspectives of the Clinical Utility of Pharmacogenomics in Solid Organ Transplantation
Skaggs Scholar Program, The focus of the study is to assess stakeholder perspectives regarding the clinical utility of pharmacogenomic (PGx) testing following kidney, liver, and heart transplantation. The study conducted by individual semi-structured interviews and focus groups with kidney, liver, and heart transplantation patients and providers.
Reducing Hospital Utilization (Readmissions and ED) Community Pharmacist Medication Reconciliation Program
United Healthcare, A longitudinal study seeking to reduce hospital reutilization (readmission and ER utilization) by adding community pharmacists to the care team. The objective of the study is to conduct and evaluate implementation of a community pharmacy based transitions of care program (PharmD_TOC)for high-risk post-discharge patients. The study runs from September 2016 to January 2021.
Multidimensional Efficacy of Canukinumab vs. Triamcinolone for Gouty Arthritis Treatment
Novartis Pharmaceuticals, Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, may be a potential therapeutic option for treating acute gout attacks and delaying new attacks in these patients (pts). Efficacy and safety of canakinumab was previously demonstrated in two 12-week, multicenter, double-blind, double dummy, active controlled trials (β-RELIEVED [N=228]; β-RELIEVED II [N=226]).1 Health-related quality of life was also measured in these studies, but not all patients completed each questionnaire. Therefore, a composite health outcomes response endpoint was developed to better interpret each patient’s overall response to treatment.
Medication Regimen Complexity Methods and Measurement in Defined Clinical Populations
Skaggs Scholars Program, An investigation of medication regimen complexity in four disease areas (hypertension, diabetes, geriatric depression and HIV), and additional measures of medication risk that should also be included in assessing the “complexity” of medication regimens in these patient populations, as a method of identifying patients who may benefit most from pharmacist intervention.
Pilot Project for Medication Therapy Management (MTM) – PharmD/MD Collaborative Practice in Primary Care.
National Institutes of Health (NIH) - National Heart, Lung and Blood (NHLBI - 1RC2HL101811-01), A randomized, pragmatic, clinical trial of hypertensive patients randomly selected to receive care from a pharmacist within a PharmD-MD Collaborative Practice team in a university primary care clinic.
A pilot study of a pharmacist-led Medication Therapy Management Services (MTMS) in Mental Health Clinic
California Department of Healthcare Services, Challenges and opportunities associated with needs assessment, implementation, and reimbursement of a psychiatric pharmacist medication therapy management (MTM) clinic.
Validation of the Gout Assessment Questionnaire (GAQ) in a non-clinical trial population.
TAP Pharmaceuticals, The objectives of this study were to further the development of a gout-specific quality of life instrument to enhance its use in clinical practice and to evaluate the psychometric properties of the new Gout Assessment Questionnaire (GAQ2.0) in a large community-based population.
Gout Impact (GI of GAQ2.0) Responsiveness and Minimal Important Difference Evaluation
TAP Pharmaceuticals, A longitudinal study of gout patients investigating the responsiveness and minimal important difference (MID) of the GAQ2.0 to aid interpretation of results when the instrument is used in clinical trials or clinical practice to monitor change in gout status.